9995 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RemeGen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$30.25 |
| 52 Week High | HK$50.30 |
| 52 Week Low | HK$14.96 |
| Beta | 0.55 |
| 1 Month Change | 3.60% |
| 3 Month Change | 77.94% |
| 1 Year Change | -21.02% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9995 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.3% | 3.0% | 4.1% |
| 1Y | -21.0% | -34.4% | -2.2% |
Return vs Industry: 9995 exceeded the Hong Kong Biotechs industry which returned -34.4% over the past year.
Return vs Market: 9995 underperformed the Hong Kong Market which returned -2.2% over the past year.
Price Volatility
| 9995 volatility | |
|---|---|
| 9995 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 9995's share price has been volatile over the past 3 months.
Volatility Over Time: 9995's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3,615 | Jianmin Fang | www.remegen.com |
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
RemeGen Co., Ltd. Fundamentals Summary
| 9995 fundamental statistics | |
|---|---|
| Market cap | HK$25.73b |
| Earnings (TTM) | -HK$1.66b |
| Revenue (TTM) | HK$1.35b |
12.1x
P/S Ratio-9.8x
P/E RatioIs 9995 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9995 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.25b |
| Cost of Revenue | CN¥306.53m |
| Gross Profit | CN¥938.62m |
| Other Expenses | CN¥2.47b |
| Earnings | -CN¥1.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.86 |
| Gross Margin | 75.38% |
| Net Profit Margin | -123.39% |
| Debt/Equity Ratio | 53.2% |
How did 9995 perform over the long term?
See historical performance and comparison